Overview

Dose-Finding Study of E7070 in Combination With Irinotecan

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
E7070 and irinotecan will be administered to patients with GI tract, pancreatic or lung tumors on Days 1 and 8 of a 21-day cycle, or Days 1 and 15 of a 28-day cycle according to one of two E7070 dose escalation schemes.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Camptothecin
Irinotecan
N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide